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Abstract: 
 
During the 2017 Biennial meeting, the American Academy of Veterinary Pharmacology and 
Therapeutics hosted a one-day session on the influence of population variability on dose-
exposure-response relationships.  In Part I, we highlighted some of the sources of population 
variability.  Part II provides a summary of discussions on modeling and simulation tools that 
utilize existing pharmacokinetic data, can integrate drug physicochemical characteristics with 
species physiological characteristics and dosing information, or that combine observed with 
predicted and in vitro information to explore and describe sources of variability that may 
influence the safe and effective use of veterinary pharmaceuticals. 
 
*  Communicating author 
a  This article reflects the views of the author and should not be construed to represent 
FDA’s views or policies 
 Modeling and Simulation to Accelerate Understanding Sources of Variability in Animal 
and Translational Health. 
 
Introduction 
Computational modeling and simulation (M&S) is rapidly increasing in its acceptance as an 
important tool for describing, predicting and understanding how chemicals interact with 
biological systems (Lin et al., 2016).  It can facilitate our appreciation of the sources of 
pharmacokinetic (PK) variability in a population, be it due to endogenous (e.g., enzyme 
polymorphisms, gender, age) or exogenous (drug-drug interactions, nutrients, disease, stress) 
factors.  When applied correctly, M&S can decrease the financial and societal costs of drug 
development by optimizing study designs and by reducing the size and numbers of in vivo 
studies, thus satisfying the principles of Replacement, Reduction and Refinement (the “3R’s). 
The availability of powerful desktop computers and user-friendly software have eliminated 
barriers to applying computational modeling in veterinary pharmacology and has shifted the 
challenge from one of software accessibility to that of its appropriate use.  
 
Within the framework of the M&S arsenal, Monte Carlo simulations can be used to address 
uncertainties associated with interacting variables within real-life scenarios. Using repetitive 
random sampling from known distributions of model parameters, population dose-exposure 
characteristics can be generated. A well-known example of this application is the estimation 
of pharmacokinetic-pharmacodynamic (PK-PD) cutoff values when establishing 
antimicrobial clinical breakpoints.  For example, using the distribution of PK parameter 
values derived from population PK studies, a specified dosing regimen, and a PK-PD target, 
we can define the minimum inhibitory concentration (MIC) at which 90% of the treated 
patients will achieve that PK-PD target (Maaland et al, 2013).  Alternatively, it can be used to 
estimate the doses needed to achieve some targeted therapeutic effect (Dorey et al., 2017; 
Rey et al., 2014).  
 
In keeping with our appreciation of the importance of these tools to support veterinary drug 
product development and use, an international group of modeling scientists were convened to 
promote and optimize the practice of M&S in animal health [the Animal Health Modeling 
and Simulation Society (AHM&S)] (Mochel et al., 2013b).  
 
Approaches to the development of models describing and predicting blood level profiles can 
be described as top-down, bottom-up, or middle-out (Jamei et al., 2009; Tsamandouras et al., 
2015).    
 
Top-down:  The fitting of blood level profiles to mathematical  equations that define pertinent 
PK parameters and describe the location (e.g., means and medians) and variability associated 
with these parameters.  The variability is further modeled in an effort to explain the sources 
of this variability (population subgroupings).  The explained sources of variability can then 
be separated from the unexplained (random) error.  The top-down approach can be used to 
support individualized dosage adjustments or to predict the dose-exposure relationships that 
may be observed in individuals that are within the modeled subgroup.  These models are 
often empirical in nature and lack interpretability in terms of specific mechanisms (Duwal 
and von Kleist, 2016).  However, they satisfy the principles of parsimony (also known as 
‘Ockham's Razor’) whereby the descriptive model is optimized with the fewest parameters. 
 
Bottom-up: A systems approach integrating drug physicochemical characteristics, patient 
characteristics, drug PK (where volume of distribution and clearance can be specifically 
modeled in accordance with observed PK profile information), transporter function, and 
enzyme abundance and kinetics.  The models are used to predict the distribution of blood 
level profiles likely to be observed across a patient population.  These models are also 
invaluable for exploring “what if” scenarios, for identifying the rate limiting factors in drug 
absorption and clearance, predicting drug-drug interactions, for dosage regimen selection, 
and for predicting dose-exposure relationships in the presence of polymorphisms in enzyme 
or transporter functions (Darwich et al., 2017; Margolskee et al., 2017):  
 
Depending upon the available information and the objective for employing this method, the 
bottom-up approach may be executed using either fully mechanistic or semi-mechanistic 
models: 
 
 Fully mechanistic model:  PK predictions are generated by integrating the full PBPK 
model (host physiology, drug physicochemical characteristics, formulation effects, 
and trial design) with the underlying processes driving drug absorption, distribution, 
metabolism and elimination. These models can segregate processes of absorption, 
distribution and elimination.  Drug clearance is typically estimated through the use of 
in vitro metabolism data. Since the resulting models do not rely on any in vivo data to 
arrive at the model input parameters, these are considered fully mechanistic models.  
However, purely mechanistic models are often difficult to establish due to information 
gaps present in the necessary in vitro metabolic data.  For this reason, in vivo 
clearance estimates (e.g., from published sources, potentially from a different 
population than that being modeled) are input into the model and a retrograde 
calculation used to derive an “in vitro intrinsic clearance”.  That estimated value is 
used to generate the species-specific systemic clearance value using physiological 
scaling parameters to harness the inter-individual variability of that species (T’jollyn 
et al., 2015). Such models still qualify as being fully mechanistic because predictions 
reflect all identified sources of population variability.  
 Semi-mechanistic model: existing PK data such as volume of distribution and 
clearance are set as the specified model parameter values.  In this case, the 
opportunity to estimate the inter-individual variability is lost.  However, a fully 
mechanistic approach can still be used to explore the process of oral drug absorption.  
Semi-mechanistic methods are often used when establishing in vivo/ in vitro 
correlations, predicting formulation effects on drug bioavailability, or for formulation 
optimization.  
 
Middle-out: This is a hybrid of bottom-up and top-down approaches where observed clinical 
data (‘top down’) are examined from the perspective of predictions derived through the use of 
mechanistic models (bottom-up).  The resulting fitted output values are used to refine the 
PBPK model in accordance to the changes necessary to minimize the difference between 
observed and fitted values (Tsamandouras et al., 2015; Zhuang and Lu, 2016).  While this 
approach to M&S can potentially be a powerful alternative to traditional compartmental or 
population-based modeling methods, it is important to recognize it also has a substantial risk 
of generating model parameter values that while providing a good fit to the observed data, 
may lack biological relevance (or may lack logical rationalization as to the fitting of that 
parameter).  Therefore, investigators should use the middle-out approach with great caution, 
acknowledging the potential limitations in their data interpretation and in predictions 
generated via model extrapolation. 
 
The relationship between these three approaches is illustrated in Figure 1. 
 
Nonlinear mixed-effects (NLME) models 
 
NLME modeling is typically a top-down approach that is used to describe the disposition 
kinetics of therapeutic drugs and to identify sources of population PK variability.  
 
Prior to the 1970’s, population parameters were estimated by pooling the individual subject 
data into a single concentration-time profile, ignoring between-subject differences (referred 
to as ‘naïve pooling’).  In subsequent years, the individual subject data were fitted separately 
and the average parameter values were determined.  This method of data analysis is often 
referred to as a  ‘two-stage approach’. Both naïve pooling and two stage approaches are 
subject to potential bias due to problems with dosing compliance or to missing data (Mould 
and Upton, 2012).   
 
A major shift in population PK characterization occurred when NLME models integrated into 
the therapeutic drug monitoring of heart disease patients to optimize their digoxin dosing 
regimens (Sheiner et al., 1972). The authors proposed a quantitative approach for analyzing 
clinical sparse data, recognizing that the relationship between observed data and model 
parameters was non-linear.   
 
When using naïve pooling or two stage methods, between-subject variability is perceived as 
‘noise’ that should be overcome.  Consequently, these approaches often lead to the use of 
complex study designs and restrictive inclusion criteria (Ette and Williams, 2004). In 
contrast, the core attribute of NLME models is its ability to separate the (between- and 
within-subject) variability from the measurement error (noise). In so doing, much of the 
between-subject variability can be explained by identifying influential population 
characteristics (e.g. age, bodyweight, gender or breed).  These characteristics can then be 
incorporated into the model structure to further expand its exploratory value. The residual 
(unexplained) variations in drug concentrations or responses consists of within-subject 
variability, inter-occasion variability (e.g. change in oral bioavailability between dosing 
sequences), bioanalytical measurement error, and model misspecification (i.e., approximation 
errors associated with the mathematical description of the true underlying biology).  
 
The use and development of NLME PK-PD models in human medicine continues to expand 
due to efforts to identify covariates describing physiological factors known to affect drug 
disposition and/or responses. They can also be used as a framework to conduct meta-analysis 
studies across various published literature (Li et al., 2014, 2015; Ogungbenro and Aarons, 
2014), an application that could have widespread applications in veterinary pharmacology. 
Within animal health, published examples of NLME modeling are also available (e.g., Silber 
et al., 2010; Cox et al., 2011; Fink et al., 2013; Pelligand et al., 2016, Mochel et al., 2013a, 
2014, 2015) and have been described in a recent review article by Bon et al. (2017).  
Interested readers can refer to these publications for further details.    
 
Physiologically-Based Mechanistic Oral Absorption Modeling in Dogs: 
 
Physiologically based pharmacokinetic (PBPK) models linked with in vitro – in vivo 
extrapolation (IVIVE) techniques form a bottom-up platform integrating diverse information 
related to species (physiology & anatomy) and drug parameters.  The models then translate 
these diverse sources of information into a description of drug PK properties, enabling 
investigators and clinicians to prospectively predict PK profiles.  These predictions can be 
used to reduce the need for in vivo data and is particularly useful during initial stages of drug 
product development (predicting the impact of formulation and/or patient characteristics on 
dose-concentration-exposure relationships).  However, model qualification and verification 
ultimately necessitates an evaluation of how well the in silico predictions compare to that of 
the actual in vivo data. 
 
The Simcyp PBPK platform (human and animals) is based on an original and unique concept 
of an ‘inter-linked component’ structure that enables a separation of trial design parameters 
(dose, route, frequency of administration etc.), animal (species) parameters (system-anatomy, 
physiology etc.) and drug parameters (drug physicochemical characteristics). When 
interacting with each other via mechanistic – IVIVE models, these parameters determine 
predicted values for drug absorption, distribution, metabolism, transport and elimination 
(Jamei 2016) (Figure 2).   
 
Using this framework, other complex modular components can be added such as: 
a. The Advanced Dissolution, Absorption and Metabolism (ADAM) model to 
mechanistically predict absorption of orally administered drugs 
b. Permeability limited liver, gut, kidney and brain models to study the effect of efflux 
and uptake transporters in the tissue organ of interest 
 Although this discussion has focused on the Simcyp PBPK platform, numerous other 
programs are also available.  Each one presents its own unique set of attributes and 
assumptions and the selection of one over the other often reflects personal preference (e.g., 
see Margolskee et al., 2017b).  Examples of available software tools include GastroPlusTM 
(http://www.simulations-plus.com/assets/GastroPlus_1-24-17.pdf), GI-Sim (Sjögren et al, 
2013), and PK-SimR (http://www.systems-biology.com/products/PK-Sim.html).  
 
Regardless of the platform selected, when a well-informed PBPK model is coupled with 
reliable estimates of intrinsic drug parameter values (internal validation) and its performance 
has been confirmed using external datasets (external validation), the prediction model 
becomes more robust. This approach is commonly referred to as an ‘in vitro-in vivo 
extrapolation linked PBPK approach’ (PPBK-IVIVE) (Rostami, 2012). Furthermore, the 
separation of systems (species) parameters from the drug parameters also enables the 
investigation of ‘what-if’ scenarios and model extrapolation.  This extrapolation may take the 
form of translating data generated in a normal healthy beagle population to predict profiles 
that may occur in a population of dogs from another breed, to dogs expressing an enzyme or 
transporter polymorphism with a given polymorphism (enzyme or transporter), or in dogs 
associated with a difference in a particular physiological attribute such as altered renal 
function, faster gastrointestinal transit time, or a difference in the percentage of body fat.   
 
There are numerous published examples where PBPK software has utilized canine-specific 
population models to explore the critical factors influencing in vivo drug absorption.  For 
example: 
 
 The importance of particle size on the oral absorption of a low solubility compound, 
cilostazole, was studied using PK-SimR in beagle dogs (Willmann et al., 2012).   
 A comparison of human and canine oral absorption of various experimental 
formulations of ciprofloxacin was generated using GastroPlusR (using both the human 
population module and the beagle population module), showing differences in the 
primary location of drug absorption in dogs versus humans and underscoring the role 
of absorption (as opposed to dissolution) constraints on the observed bioavailability 
limitations in dogs versus humans.  These results were consistent with the PK 
observation that sustained release ciprofloxacin formulations are inappropriate for use 
in dogs (Martinez et al., 2016, 2017). 
 The ability to model the effect of food on oral bioavailability was explored for weak 
acids (mavacoxib and celecoxib) in dogs using the beagle population module of 
Simcyp (Martinez et al., 2013).  Food effects in dogs were also accurately modeled 
for cilastazole using PK-SimR in beagle dogs (Willmann et al., 2012). 
 Most recently, a mechanistic approach was applied for predicting the oral 
bioavailability of danazol when administered across a range of formulations to beagle 
dogs.  Predictions were subsequently verified using published in vivo data. Using the 
ADAM model that divides the dog gastrointestinal tract (GIT) into 9 segregated 
segments (stomach to the colon), the rate of drug dissolution, permeability, gut 
metabolism and fraction absorbed (fa) were mechanistically predicted. A unique 
aspect of the ADAM model is its ability to assess the dynamic behavior of GIT fluid 
volumes based on GI transit times (GITT), GIT secretion rates and absorption rates. 
The impact of formulation both on in vivo dissolution and absorption were explored.  
Preliminary results from this work were presented at the European Association of 
Veterinary Pharmacology and Toxicology meeting in 2015 (Pade et al., 2015), and the 
full study is currently submitted for publication (Pade et al., 2018).   
 
Unfortunately to date, there is a gap in the publication of studies using in silico models to 
support drug development in dogs even though software programs such as GastoPlusR, PK-
SimR, and SimcypR have physiology modules specifically tailored to the beagle dog.  
Hopefully, these examples of the insights and of the efficiency that can be gained by using 
PBPK approaches will stimulate the application of this tool to support formulation 
development, for understanding the factors that can influence the absorption and in vivo 
dissolution of oral drug formulations, and sources of variability that can exist across a 
population of dogs. 
 
Practical Implications of Population Variability in the Animal Health Industry 
 
The session concluded with a presentation and discussion of the use and concern of M&S in 
animal health.  The key points addressed are provided below: 
 
 Uncertainty regarding the current regulatory framework concerning population 
variability in the drug development business? 
 
From the perspective of human therapeutics, the importance of considering both genotypic 
and phenotypic variability is recognized and therefore has been incorporated into the 
regulatory guidances both of the US Food and Drug Administration (FDA) Center for Drug 
Evaluation and Research (CDER) and of the European Medicines Agency (EMA). In 
addition to general guidelines on population PK (CHMP/EWP/185990/06 and FDA GFI 
1999) and on the use of PBPK models (CHMP/211243/2014 and FDA draft GFI 2016), 
specific guidelines are now available for a variety of factors that can alter drug dose-
exposure-response relationships.  Furthermore, the CHMP/37646/2009 and FDA GFI 2013 
encourage early implementation of pharmacogenomics testing during the clinical phases of 
product development to promote a more complete understanding of the kinds of PK and PD 
variability that should be considered within the target patient population.  
 
The potential impact of genotypic and phenotypic variability has not been comparably 
appreciated or addressed by either the US or by the European regulators of veterinary drug 
product applications.  Currently, due to the absence a legal framework supporting a 
requirement for the submission of PK data, the FDA Center for Veterinary Medicine (CVM) 
cannot routinely  require such information to be generated as part of a new animal drug 
application.  In contrast, PK data generated at the clinical dose are required within Europe for 
veterinary drug registration and the EMA’s Committee for Medicinal Products for Veterinary 
Use (CVMP) has published a draft guideline on the conduct of PK studies in the target animal 
species 
(http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2017/11/WC
500238890.pdf).   
 
It is interesting to note that the 2017 CVMP draft guidance includes concepts of population 
PK as was originally addressed in the January 2016 EMA/CVMP concept paper titled 
“Concept paper for the revision on the guideline for the conduct of pharmacokinetic studies 
in target animal species (EMEA/CVMP/133/99-Final)”. This concept paper briefly pointed to 
the need to consider sources of veterinary PK variability as potentially captured via 
population PK studies, the use of in silico PBPK models, by assessing the difference in PK in 
healthy versus diseased animals, and by developing an understanding of the impact of 
pharmacogenetic variation on population dose-exposure-response relationships.  In that 
regard, should be noted that this approach has already been used to support pre- and post-
marketing adjustments in dosage regimen for the veterinary drug, mavacoxib (Cox et al., 
2011).   
 
The other mention of population variability within the veterinary regulatory framework is 
embedded in the latest revision of the Guideline for the demonstration of efficacy for 
veterinary medicinal products containing antimicrobial substances (EMA/CVMP/627/2001-
Rev.1). For the selection of clinical breakpoints for veterinary antimicrobial drugs, the 
guideline encourages the use of Monte Carlo simulations (see supra), using PK data for 
stochastic estimation of antimicrobial exposure in the target population at the licensed dose.   
 
 Pinpointing the origin of the variability in veterinary species: 
 
Although not originally conducted to support veterinary drug development, the study by 
Paulson et al.  (1999) was a landmark paper within veterinary community because it revealed 
a genetic origin for the large differences in celecoxib metabolism observed across a group of 
242 laboratory beagles. Since then, similar within-breed variability in PK (driving the 
observed variability in the duration of clinical efficacy) was reported with the veterinary drug 
cimicoxib (Jeunesse, et al., 2013).  Although clinically relevant variability in population PK 
was not observed among studied client-owned dogs (representative of 4 different breeds), 
Part I of this AAVPT meeting report provides numerous examples of clinically relevant 
polymorphisms now recognized across veterinary species (Martinez et al., submitted for 
publication)   
 
Understanding some of the potential reasons for sub-optimal responses is grounded in the 
link between PK and PD (Toutain and Lees, 2004), population variability (sources of inter-
animal variability identified through the inclusion of explanatory covariates), and inter-
occasion variability (where the kinetics may vary within the same subject dosed one several 
occasions).  Sources of PD variability include the variability associated with disease 
expression, the time course of its clinical manifestation, and the relationship between drug 
exposure and clinical effect. Experienced clinicians can address the issue of PD variability 
by: (i) monitoring the clinical response (e.g., the blood pressure in response to 
antihypertensive therapy); (ii) monitoring biomarkers of a clinical response (e.g., glucose 
curve, international normalized ratios for anticoagulation); (iii) the use physiologically 
relevant information to adjust dosage (e.g., carboplatin dose informed by GFR in cats, see 
Bailey et al. 2009); and (iv) relying on therapeutic drug monitoring.  Nevertheless, adverse 
drug reactions (including lack of efficacy) still occur due to variability in dose-exposure-
response relationships.     
  
 What could the future look like? 
 
The “hot button question” was whether (when) it is appropriate to document variability in the 
target population within the drug development process? A SWOT 
(Strength/Weakness/Opportunity/Threat) analysis was proposed based upon results obtained 
when interviewing a sample of representative members of the veterinary industry, regulatory 
bodies and academia (Figure 3):    
 
The results of this analysis can be summarized as follows: 
 
Perceived Strengths: 
Internal resources can contribute to the usefulness of documenting population variability in 
animal species through: (i) identification of relevant covariates; (ii) dose optimization; (iii) 
providing an opportunity to use sparse PK data to document clinical population behavior; (iv) 
the identification of factors that can alter drug kinetics in edible tissues; and (v) provision of 
an approach for handling situations where dose is uncertain (for example when the drug is 
given to a group in food or water). With the availability of PK competency within a drug 
company, a small increase in effort (e.g., training) could yield highly rewarding results. 
 
Perceived Weaknesses: 
There continues to be numerous factors that lead to a resistance to the documentation of 
sources of population variability. These include: (i) a perceived lack of incentive, as this 
information is not currently encouraged or recommended by regulatory agencies, particularly 
the USFDA CVM;  (ii) a limited awareness of altered therapeutic (safety and effectiveness) 
profiles or drug residue levels that have been documented in animal health due to drug-drug 
interactions, polymorphisms in influx or efflux transporters or in drug metabolizing enzymes; 
iii) a lack of published studies showcasing the impact of physiological and environmental 
factors on drug PK and therefore PD and residues; iv) a lack of awareness of and training in 
veterinary population PK; and (iv) concerns associated with potential additional cost, time 
delays, regulatory oversight, and the need to outsource these analyses. 
 
Perceived Opportunities: 
M&S approaches serve as highly effective tools for combining preclinical and clinical data 
to: (i) de-risk dose-determination studies; (ii) enrich clinical trial design (allows for the 
recruitment of an animal population that is more likely to respond to the drug); (iii) inform 
the drug sponsor of conditions that may necessitate therapeutic drug adjustments; and iv) 
provides a strong basis for the understanding of adverse drug reaction by clinicians and 
during post-marketing surveillance. Moreover, M&S provides an important mechanism by 
which once can reduce animal use (3Rs), especially though model and data sharing, thereby 
promoting a OneHealth solution to the problem of antimicrobial resistance. 
 
Perceived Threats: 
Expressed concerns resisting the documentation of variability in target population include: (i) 
the fear that variability documentation may become an additional compulsory requirement 
imposed by regulators; (ii) a perceived lack of relevance and motivation for this information 
in veterinary medicine; (iii) concerns that regulators will punish innovation (lack of reward 
and more constraints imposed); and iv) this could lead to a re-opening of flexible labelling 
concepts to address potential needs to adjust dose or withdrawal times as a function of drug-
drug interactions or population subgroups.  
 
Future recommendations: 
 
Based upon recommendations and expressed comments received during this one-day session, 
it is concluded that the following initiatives should be explored to encourage and facilitate the 
adoption of population variability characterization by the veterinary drug industry: 
 
 Regulators and industry should showcase proof of concept cases where population 
variability characterization led to successful registration outcomes.  There needs to be 
greater attention given to the sharing of evidence that this business model is cost effective 
for companies that wish to make the best possible use of PK and PD data accumulated 
during all stages of drug product development. Regulators should consider incentivizing 
the use of PK and M&S approaches through (for example) the possibility of omitting 
certain studies (e.g., dose-determination studies) and/or the acceptability of confirming 
efficacy in one or (or limited) dosage regimens in clinical trials. Industry-government 
discussions should occur early during the drug application process to facilitate 
implementation of population PK-PD as part of the application dossier.  
 Academia and industry should be encouraged to increase their level of interaction through 
the development of collaborative research projects, the sharing of expertise, and through 
the development of model banks such as those provided by the Drug Disease Model 
Resources (DDMoRe) consortium (http://www.ddmore.eu/). In veterinary drug 
development, innovation in population PK and pharmacometrics is often driven by 
academic centers rather than by government due to the limited resources of regulatory 
agencies. Scientific associations such as the AAVPT, the European Association of 
Veterinary Pharmacology and Toxicology (EAVPT), the AHMSS, and specialist colleges 
such as the European College of Veterinary Pharmacology and Toxicology (ECVPT) 
should rejuvenate and develop comprehensive training programs in pharmacometrics and 
computational pharmacology to meet the evolving needs of the industry and of the animal 
health community 
(http://www.ema.europa.eu/docs/en_GB/document_library/Minutes/2009/11/WC5000099
23.pdf). 
 Training should be offered to promote progression to different competency tiers, 
including: (i) basic “essential awareness”; (ii) intermediate knowledge and skillset 
development for assessors at regulatory agencies; and (iii) expert scientist through the 
development of tailor-made courses. Importantly, joint training for assessors and 
pharmaceutical industry could help stakeholders and regulators to “speak the same 
language”.   
 Software developers can play a pivotal role in ensuring the acceptance and use of PK/PD 
and population PK modelling and PBPK software by outreach to non-specialist scientists 
within industries.  This outreach could take the form of webinars and workshops.  
 
Concluding Thoughts 
 
When studying the pharmacology of a drug, the modeling approach (top-down versus 
bottom-up or a hybrid of the two) should be chosen based on research objectives and by what 
is already known about a compound. If very little is known, empirical and descriptive models 
can be invaluable for providing an initial understanding of the interactions that can occur 
between the drug and a biological system. Empirical (model fitting) approaches are also 
appropriate if the research goal is very specific (e.g., to compare the bioavailability between 
two formulations of a given drug). As our knowledge about a drug increases, the 
development of  mechanistic models become possible, and these can then be used to 
extrapolate and predict the outcomes of different ‘what-if ‘scenarios to gain insights into 
formulation effects and population differences in drug exposure. 
 
While therapeutic drug monitoring has contributed to an appreciation of the population 
variability in human medicine, it has been rarely used within the framework of veterinary 
medicine.  Considering that, for example, 105 genotypes have been identified for human 
CYP2D6 (with 29 of these associated with little to no activity) 
[http://www.cypalleles.ki.se/l], it is easy to see the challenges that would accompany efforts 
to predict population variability solely based on genetics. To address this gap and in addition 
to therapeutic drug monitoring, several in silico tools are available to help unravel these and 
other complex situations.  Whether it involve the use of mechanistic models to understand the 
PK implications of polymorphic forms of drug metabolizing enzymes and transporters or the 
use of computational models to identify critical covariates within a population, the 
availability of mechanistic models enables experimental data (both in vivo and in vitro) to be 
far more information-rich than it has been in the past. We can continually adjust our 
expectations as more data are collected across a range of samples from the population of 
animal patients.  
 
The necessary tools and knowledge are available. The importance of understanding the 
various sources of population variability and the corresponding utility of data assessments 
using M&S computational tools has been showcased in Parts I and II of this 2017 AAVPT 
meeting report. Whether using the top-down, bottom-up, or middle-out approach, integrating 
M&S into efforts to understand the relationship between a drug or formulation and the 
behavior of the drug within the targeted animal population will be invaluable for meeting the 
ever-changing therapeutic needs associated with animal health. As a community, we need to 
encourage the generation and evaluation of drug and drug product PK as a critical component 
of efforts to obtain drug/drug product understanding.  There needs to be more widespread use 
of in silico tools for population predictions, data interpretation, and formulation development.   
Importantly, we need to train our young scientists to understand the importance of PK and 
sources of population variability and how to appropriately apply in silico modeling 
procedures, appreciating its pharmaco-statistical underpinnings and recognizing the 
importance of identifying/challenging their model’s underlying assumptions.  
 
It is the hope of the authors of this report that the information conveyed in Part II illustrate 
the strengths and opportunities for the described M&S approaches to improve the efficiency 
of the drug product development process (formulation optimization, clinical trial design, and 
safety and effectiveness trial analysis), to provide information to veterinary practitioners that 
will support prescribing practices that are in accordance with factors that may influence 
product safe and effective use, and to serve as an evaluation tool for regulators during pre-
market product assessment, protocol development, and during the evaluation of potential 
causes for adverse post marketing experience reports. It is now up to the community of 
veterinary pharmacologists and those of us involved in the development and/or regulation of 
veterinary pharmaceutical to generate and use this information appropriately.  
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Figure 1. An illustration of the interrelationship and unique attributes associated with the top‐
down, bottom‐up and middle out approaches to M&S  
 
 
Figure 2. Separation of Systems (species) data versus Drug data and Trial Design 
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